Samarawickrama Lucewicz Ania, Rhou Yoon Ji Jina, Melov Sarah, Elhindi James, Patel Shrujna, Flood Victoria, Smith Ben J, Usherwood Tim, McNab Justin, McClean Mark, Cheung Ngai Wah, Pryce Karena, Pasupathy Dharmintra
Reproduction and Perinatal Centre, The University of Sydney Faculty of Medicine and Health, Sydney, New South Wales, Australia.
General Practice Clinical School, The University of Sydney Faculty of Medicine and Health, Sydney, New South Wales, Australia.
BMJ Open. 2025 Mar 7;15(3):e090930. doi: 10.1136/bmjopen-2024-090930.
The Improving maternal and PeRinatal Outcomes aMongst wOmen with and without obEsity (PROMOTE) cohort study is a prospective pregnancy cohort study that seeks to test current assumptions and understanding of cardiometabolic disease and risk during pregnancy. The demographic shift among pregnant women, including older age and increasing obesity, has resulted in an increased risk of cardiometabolic complications during pregnancy and over the lifetime for mother and offspring. Unfortunately, lifestyle interventions during pregnancy have not yet produced clinically meaningful outcomes. Furthermore, cohort studies in pregnancy are costly and have selection bias due to study burden and attrition. There is an urgent need for high-quality observational data collected pragmatically about cardiometabolic health and determinants during pregnancy, to identify subgroups at highest risk and to provide rich contextual information around the interplay of clinical and social determinants.
The PROMOTE cohort study is a prospective pregnancy cohort study recruiting pregnant participants <16 weeks' gestation at a large urban public teaching hospital with high social and cultural diversity in Sydney, Australia. Participants are surveyed about their physical activity levels, dietary quality, emotional well-being and sociodemographic status using validated tools. Participants are consented for biobanking and for use of routinely collected clinical and social data, including medical conditions, body mass index, blood pressure and glycaemia. Follow-up is from routinely collected data. Pregnancy and birth outcomes include maternal and neonatal pregnancy and birth outcomes include gestational diabetes mellitus, hypertensive disorders of pregnancy and preterm birth. Postnatal and longitudinal data collection is planned.
The study has been approved by the Western Sydney Local Health District Human Research Ethics Committee (2021/ETH00287). The study will disseminate results by academic publication, conference presentations and targeted implementation partnerships.
Retrospectively registered with the Australian New Zealand Clinical Trials Registry (registration number: ACTRN12624001344583).
改善肥胖和非肥胖孕妇的母婴结局(PROMOTE)队列研究是一项前瞻性妊娠队列研究,旨在检验当前对妊娠期心脏代谢疾病及其风险的假设和认识。孕妇群体中的人口结构变化,包括年龄增长和肥胖率上升,导致孕期以及母亲和后代一生中发生心脏代谢并发症的风险增加。遗憾的是,孕期的生活方式干预尚未产生具有临床意义的结果。此外,妊娠队列研究成本高昂,且由于研究负担和人员流失存在选择偏倚。迫切需要切实收集有关妊娠期心脏代谢健康及其决定因素的高质量观察数据,以识别风险最高的亚组,并围绕临床和社会决定因素的相互作用提供丰富的背景信息。
PROMOTE队列研究是一项前瞻性妊娠队列研究,在澳大利亚悉尼一家具有高度社会和文化多样性的大型城市公立教学医院招募妊娠<16周的孕妇参与者。使用经过验证的工具对参与者进行身体活动水平、饮食质量、情绪健康和社会人口学状况的调查。参与者同意进行生物样本库储存,并同意使用常规收集的临床和社会数据,包括医疗状况、体重指数、血压和血糖。通过常规收集的数据进行随访。妊娠和分娩结局包括母亲和新生儿的妊娠和分娩结局,如妊娠期糖尿病(GDM)、妊娠高血压疾病和早产。计划进行产后和纵向数据收集。
该研究已获得西悉尼地方卫生区人类研究伦理委员会批准(2021/ETH00287)。该研究将通过学术发表、会议报告和有针对性的实施伙伴关系传播研究结果。
追溯注册于澳大利亚新西兰临床试验注册中心(注册号:ACTRN12624001344583)。